Abstract
Drug therapy for detrusor hyperactivity can be directed either at decreasing bladder contractility or decreasing sensory input during filling. The agents available to accomplish these purposes are reviewed. Certain questions are raised regarding studies assessing the action of pharrnacologic agents on lower urinary tract storage failure.